Bold Therapeutics, based in Vancouver, British Columbia, is a clinical-stage oncology company focused on developing BOLD-100, a ruthenium-based small molecule therapeutic, that appears to significantly enhance the activity of a wide range of other anti-cancer therapies by disabling a critical and previously untargeted cancer resistance, survival and proliferation pathway. Based on compelling preclinical and early clinical results, Bold Therapeutics is focusing its development efforts on some of the most challenging cancer indications where existing therapies are largely ineffective, resulting in a significant unmet medical need.
Founded in 2021, Dr Angela Genge brings her 25+ years of experience as an internationally recognized opinion leader in the spaces of drug design and rare disease to Genge Partners.
Combining the efficiencies of a private practice setting and the expertise of an academic clinical trial setting, Genge Partners will provide access to patient populations and operational expertise to you and your partners.
Over the course of her career, Dr Genge has championed upcoming and new therapies to international audiences including South Africa, Colombia, the Gulf Region, North America and Europe.
The George and Fay Yee Centre for Healthcare Innovation, (CHI), was established as a partnership between the University of Manitoba and the Winnipeg Regional Health Authority. CHI platforms include clinical trials, data science, knowledge translation, knowledge synthesis, project management, health systems performance and evaluation. The centre brings together leaders and practitioners from all disciplines to ensure that the latest evidence is translated into improved patient outcomes, enhanced patient experiences and improved access to care for Manitobans.